GABRB3: A Potential Drug Target for Neurodegenerative Diseases

Target Name: GABRB3

NCBI ID: G2562

GABRB3

Other Name(s): EIEE43 | Gamma-aminobutyric acid type A receptor beta3 subunit, transcript variant 3 | Gamma-aminobutyric acid type A receptor subunit beta3, transcript variant 1 | GABAA receptor beta-3 subunit | GABRB3 variant 1 | gamma-aminobutyric acid (GABA) A receptor, beta 3 | Gamma-aminobutyric acid receptor subunit beta-3 (isoform 2) | GABRB3 variant 5 | gamma-aminobutyric acid type A receptor beta3 subunit | gamma-aminobutyric acid type A receptor subunit beta3 | GABRB3 variant 4 | GBRB3_HUMAN | DEE43 | gamma-aminobutyric acid A receptor beta 3 | Gamma-aminobutyric acid (GABA) A receptor, beta 3 | Gamma-aminobutyric acid receptor subunit beta-3 (isoform 1) | Gamma-aminobutyric acid type A receptor beta3 subunit, transcript variant 5 | GABRB3 variant 3 | GABA(A) receptor subunit beta-3 | GABRB3 variant 2 | Gamma-aminobutyric acid type A receptor subunit beta3, transcript variant 4 | Gamma-aminobutyric acid type A receptor subunit beta3, transcript variant 2 | Gamma-aminobutyric acid receptor subunit beta-3 (isoform 4) | Gamma-aminobutyric acid receptor subunit beta-3 | Gamma-aminobutyric acid receptor subunit beta-3 (isoform 3) | ECA5 | gamma-aminobutyric acid receptor subunit beta-3 | GABA-alpha receptor beta-2 subunit

GABRB3: A Potential Drug Target for Neurodegenerative Diseases

GABRB3 (GABrb4) is a protein that is expressed in the brain and is known for its role in the regulation of synaptic plasticity. Synaptic plasticity is the ability of the brain to change and adapt over time, and is an important factor in the development and maintenance of neural circuits. GABRB3 has been shown to play a crucial role in this process, and is therefore a potential drug target or biomarker.

GABRB3 is a member of the GABRB gene family, which is known for its role in the regulation of neurotransmitter release. The protein encoded by the GABRB gene is a GABA-B subunit receptor, GABA is an important neurotransmitter , can regulate communication between neurons. GABRB3 controls communication between neurons by regulating the release of GABA, and also plays an important role in neuronal apoptosis.

In recent years, GABRB3 has been found to have potential application value in the treatment of neurodegenerative diseases. For example, GABRB3 loss is associated with the onset of Alzheimer's disease, making GABRB3 a potential therapeutic target for Alzheimer's disease. In addition, the elevation of GABRB3 may also be associated with an increased risk of neurodegenerative diseases, so the detection of GABRB3 may also be an important indicator for risk assessment of neurodegenerative diseases.

In addition to its applications related to neurodegenerative diseases, GABRB3 has also been shown to have potential applications in the treatment of neuropsychological diseases. For example, GABRB3 loss is associated with symptoms of depression, making GABRB3 a potential therapeutic target for depression. In addition, the elevation of GABRB3 may also be associated with an increased risk of depression, so the detection of GABRB3 may also be an important indicator for depression risk assessment.

In addition, GABRB3 has also been shown to have potential application value in the treatment of neurodegenerative diseases. For example, GABRB3 deletion is associated with the onset of Parkinson's disease, making GABRB3 a potential therapeutic target for Parkinson's disease. In addition, the elevation of GABRB3 may also be associated with an increased risk of Parkinson's disease, so the detection of GABRB3 may also be an important indicator for Parkinson's disease risk assessment.

GABRB3 is a protein that plays an important role in the nervous system. GABRB3 has been found to have potential applications in the treatment of neurodegenerative diseases, neuropsychological disorders, and neurodegenerative disease risk assessment. In the future, with the continuous advancement of technology, GABRB3 is expected to become a new drug target or biomarker, providing new ideas and hope for the treatment of neurodegenerative diseases.

Protein Name: Gamma-aminobutyric Acid Type A Receptor Subunit Beta3

Functions: Ligand-gated chloride channel which is a component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the brain (PubMed:18514161, PubMed:22303015, PubMed:26950270, PubMed:22243422, PubMed:24909990). Plays an important role in the formation of functional inhibitory GABAergic synapses in addition to mediating synaptic inhibition as a GABA-gated ion channel (PubMed:25489750). The gamma2 subunit is necessary but not sufficient for a rapid formation of active synaptic contacts and the synaptogenic effect of this subunit is influenced by the type of alpha and beta subunits present in the receptor pentamer (By similarity). The alpha1/beta3/gamma2 receptor exhibits synaptogenic activity (PubMed:25489750). The alpha2/beta3/gamma2 receptor shows very little or no synaptogenic activity (By similarity). Functions also as histamine receptor and mediates cellular responses to histamine (PubMed:18281286). Plays an important role in somatosensation and in the production of antinociception (By similarity)

The "GABRB3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GABRB3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets